Theratechnologies’ Ibalizumab demonstrates cost-effectiveness

Theratechnologies shared data demonstrating the cost-effectiveness of ibalizumab, a monoclonal antibody antiretroviral therapy commercialized in the U.S. under the trade name Trogarzo, as an addition to optimized background regimens in heavily treatment-experienced people with HIV. The analysis, which was presented at the Academy of Managed Care Pharmacy Nexus 2023 conference in Orlando, Fla., suggests that adding ibalizumab to routine clinical care may provide payers with a cost-effective treatment option that can substantially improve outcomes for HTE individuals with HIV. “As there is an increasing urgency for closer management of healthcare costs in the U.S., payers should prioritize therapies that can clearly demonstrate cost-effectiveness,” said John Leasure, Global Commercial Officer at Theratechnologies. “Although adding ibalizumab to optimized background regimens increases the costs of care, it also increases quality-adjusted life-years, making this therapy a cost-effective component of HIV for those who are heavily treatment experienced.”